Helicobacter Pylori Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Helicobacter Pylori Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The helicobacter pylori diagnostics market is expected to register a CAGR of 7.2% over the forecast period.

The outbreak of the COVID-19 pandemic has pushed the medical device industry into action, with a race to develop both therapeutic and preventive devices. Exponentially increasing cases of the coronavirus worldwide are leading to the need for the development of novel treatments, with several clinical trials underway. Meanwhile, the manufacturers of diagnostic devices were highly focused on developing vaccines and drugs, which can also be applied in the diagnosis and treatment of COVID-19, increasing the rate of clinical trials to a great extent. The outbreak of the pandemic increased the cases of gastrointestinal diseases and other infectious diseases. For instance, as per the study titled, "Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach" published in November 2020, the gastrointestinal tract gets affected by COVID-19. It also reported that the gastrointestinal tract is considered the replication site for SARS-CoV-2. In addition, it also stated that the severity in patients suffering from COVID-19 increases who are already having gastrointestinal disorders. Helicobacter pylori diagnostics is one of the common diagnostic procedures for gastrointestinal disorders, therefore, the market witnessed a considerable growth during the pandemic.

The rising prevalence of infectious diseases and increasing awareness about the infections among people are the major drivers for the market. The most common infectious diseases caused by bacteria are Tuberculosis, Chlamydia, gonorrhea, other sexually transmitted diseases (STDs), Stomach flu (gastroenteritis), and Urinary tract infections (UTIs). For instance, according to the study titled, "The Global Prevalence of Peptic Ulcer in the World: a Systematic Review and Meta-analysis" published in December 2021, the global prevelence of peptic ulcer was around 8.4% in 2021. Similarly, as per the report published by the Medscape in April 2021, peptic ulcer disease affects approximately 4.6 million people annually in the United States. Similarly, according to the report published by the European Centre for Disease Prevention and Control in March 2021, it was reported that every year around 500,000 sexually transmitted infections are detected in the European Union, European Economic Area (EEA), and the United Kingdom. Since, helicobacter pylori diagnostics are generally recommended for the diagnostic of infectious diseases, therefore, such instances indicate that the market is expected to show significant growth rate over the forecast period.

However, stringent regulatory norms by government may likely to restrain the market growth over the forecast period.

Key Market TrendsImmunoassay Segment is Expected to Witness Growth Over the Forecast Period

An immunoassay is a test that relies on biochemistry to measure the presence and concentration of an analyte. The analyte can be large proteins, antibodies that a person has produced as a result of an infection, or small molecules. Immunoassays are highly sensitive and specific. Their high specificity results from the use of antibodies and purified antigens as reagents. This assay can be used for the diagnosis of a disease directly, by measuring the presence of antigens. In addition, it is a highly selective bioanalytical method that measures the presence or concentration of analytes ranging from small molecules to macromolecules in solution using an antibody or antigen as a biorecognition agent.

The immunoassay segment holds a significant market share in the helicobacter pylori diagnostics market and is anticipated to show a similar trend over the forecast period due to the presence of several advanced technologies such as the enzyme immunoassays which are used for the detection of antibodies. The rising prevalence of Helicobacter pylori infections and gastritis and technological advancements are the key driving factors in the immunoassay segment. For instance, as per the study titled, "Diagnosis of Helicobacter pylori Infection and Recent Advances" published in August 2021, the prevalence of gastritis was around 50.0%, which was shown from 40.7% to 56.0% and it included 20.0%–30.0% of chronic atrophic gastritis, globally in 2021. It also reported that Helicobacter pylori infection is generally consistent with the prevalence of gastritis and Helicobacter pylori positive gastritis generally accounts for more than 80.0%. Immunoassays are generally used for the detection of such infections, therefore, increasing cases of Helicobacter pylori infection and gastritis are anticipated to propel the segment growth over the forecast period.

North America is Expected to Dominate the Helicobacter Pylori Diagnostics Market

North America is expected to dominate the overall helicobacter pylori diagnostics market over the forecast period. The growth is due to factors such as the increasing number of cases of infectious diseases, increasing awareness of infectious diseases, and new product launches. For instance, in June 2021, Biomerica Inc. announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomerica’s new and proprietary Helicobacter pylori test, called hp+detect. The hp+detect product has been developed for the identification and monitoring of helicobacter pylori infection, the leading cause of duodenal and gastric ulcers, and a contributing risk factor associated with gastric cancer. Therefore, such instances are anticipated to propel market growth in the North America region.

Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and increasing cases of gastrointestinal disorders in the United States are some of the factors driving the growth of the Helicobacter pylori diagnostics market in the country. For instance, as per the journal published by the Cleveland Clinic Organization in September 2020, acute gastritis affects about 8 out of every 1,000 people in the United States every year. It also reported that chronic, long-term gastritis is less common and it affects approximately 2 out of 10,000 people in the United States every year.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

Competitive Landscape

The helicobacter pylori diagnostics market is consolidated and consists of a few major players. In terms of market share, a few of the major players are currently dominating the market. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including Thermo Fisher Scientific, Bio-Rad Laboratories, Quest Diagnostics Incorporate, Meridian Bioscience, F. Hoffmann-La Roche, Biohit Oyj, CorisBioConcept SPRL, CerTest BIOTEC, Epitope Diagnostics, Inc and Exalenz Bioscience Ltd among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.